2023 World Conference on Lung Cancer (Posters)-EP12.01. Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy

EP12.01. Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses the use of aumonertinib, a third-generation EGFR-TKI, in patients with liver dysfunction after previous EGFR-TKI treatment or patients with basic hepatopathy and EGFR-mutant NSCLC. EGFR-TKIs are commonly used in the treatment of NSCLC, but can cause liver injury as a side effect. Patients with liver dysfunction are at a higher risk for liver injury during anti-tumor treatment. <br /><br />The study aims to assess the efficacy and safety of aumonertinib therapy in this patient population. Approximately 55 patients with stage IIIB-IV NSCLC and EGFR mutations will be enrolled in the study. These patients will have previously been treated with first/second generation EGFR-TKIs and experienced drug-induced liver dysfunction or have basic hepatopathy and be eligible for EGFR-TKI treatment based on specialist evaluation. The patients will receive aumonertinib 110mg orally once daily.<br /><br />The primary endpoints of the study are the objective response rate (ORR) and liver safety, measured by various liver function markers. The secondary endpoints include progression-free survival (PFS), disease control rate (DCR), and overall survival (OS).<br /><br />This study is important as it addresses the need for optimal treatment options for lung cancer patients with liver dysfunction. By assessing the efficacy and safety of aumonertinib in this patient population, researchers hope to provide valuable insights for clinical practice. The abstract provides keywords related to the study, including NSCLC, liver dysfunction, and hepatopathy, and categorizes the research under the track of Metastatic Non-small Cell Lung Cancer - Targeted Therapy.

Asset Subtitle

Feng Luo

Meta Tag

Speaker Feng Luo

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumonertinib

EGFR-TKI

liver dysfunction

hepatopathy

EGFR-mutant NSCLC

anti-tumor treatment

efficacy

safety

objective response rate

liver function markers